Terms: = Liver cancer AND KAT6B, DKFZp313G1618, 23522, MYST4, ENSG00000156650, Q8WYB5, querkopf, qkf, MOZ2, MORF, KIAA0383, FLJ90335
6 results:
1. Selective inhibition of integrin αvβ6 leads to rapid induction of urinary bladder tumors in cynomolgus macaques.
Guffroy M; Trela B; Kambara T; Stawski L; Chen H; Luus L; Montesinos MS; Olson L; He Y; Maisonave K; Carr T; Lu M; Ray AS; Hazelwood LA
Toxicol Sci; 2023 Feb; 191(2):400-413. PubMed ID: 36515490
[TBL] [Abstract] [Full Text] [Related]
2. Low Expression of kat6b May Affect Prognosis in Hepatocellular Carcinoma.
Jiang J; Wang HJ; Mou XZ; Zhang H; Chen Y; Hu ZM
Technol Cancer Res Treat; 2021; 20():15330338211033063. PubMed ID: 34464167
[TBL] [Abstract] [Full Text] [Related]
3. Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer.
Cheng CL; Tsang FH; Wei L; Chen M; Chin DW; Shen J; Law CT; Lee D; Wong CC; Ng IO; Wong CM
Commun Biol; 2021 Jul; 4(1):888. PubMed ID: 34285329
[TBL] [Abstract] [Full Text] [Related]
4. The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis.
Mishima Y; Miyagi S; Saraya A; Negishi M; Endoh M; Endo TA; Toyoda T; Shinga J; Katsumoto T; Chiba T; Yamaguchi N; Kitabayashi I; Koseki H; Iwama A
Blood; 2011 Sep; 118(9):2443-53. PubMed ID: 21753189
[TBL] [Abstract] [Full Text] [Related]
5. A preclinical 188Re tumor therapeutic investigation using morf/cmorf pretargeting and an antiTAG-72 antibody CC49.
Liu G; Dou S; Baker S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
Cancer Biol Ther; 2010 Oct; 10(8):767-74. PubMed ID: 21099368
[TBL] [Abstract] [Full Text] [Related]
6. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.
He J; Liu G; Gupta S; Zhang Y; Rusckowski M; Hnatowich DJ
J Nucl Med; 2004 Jun; 45(6):1087-95. PubMed ID: 15181145
[TBL] [Abstract] [Full Text] [Related]
